Ocugen Past Earnings Performance
Past criteria checks 0/6
Ocugen's earnings have been declining at an average annual rate of -17.2%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 73.5% per year.
Key information
-17.2%
Earnings growth rate
49.9%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 73.5% |
| Return on equity | -125.9% |
| Net Margin | -1,088.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Ocugen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 5 | -51 | 26 | 0 |
| 30 Jun 24 | 7 | -50 | 28 | 0 |
| 31 Mar 24 | 7 | -58 | 30 | 0 |
| 31 Dec 23 | 6 | -63 | 32 | 0 |
| 30 Sep 23 | 7 | -79 | 34 | 0 |
| 30 Jun 23 | 3 | -90 | 34 | 0 |
| 31 Mar 23 | 3 | -86 | 34 | 0 |
| 31 Dec 22 | 2 | -87 | 35 | 0 |
| 30 Sep 22 | 0 | -74 | 36 | 0 |
| 30 Jun 22 | 0 | -63 | 32 | 0 |
| 31 Mar 22 | 0 | -69 | 29 | 0 |
| 31 Dec 21 | 0 | -58 | 23 | 0 |
| 30 Sep 21 | 0 | -48 | 18 | 0 |
| 30 Jun 21 | 0 | -47 | 15 | 0 |
| 31 Mar 21 | 0 | -38 | 10 | 0 |
| 31 Dec 20 | 0 | -34 | 8 | 0 |
| 30 Jun 20 | 0 | -30 | 8 | 1 |
| 31 Mar 20 | 0 | -18 | 7 | -3 |
| 31 Dec 19 | 0 | -20 | 6 | 0 |
| 30 Sep 19 | 0 | -39 | 6 | 9 |
| 30 Jun 19 | 0 | -18 | 6 | 4 |
| 31 Mar 19 | 0 | -19 | 6 | 11 |
| 31 Dec 18 | 0 | -18 | 6 | 10 |
Quality Earnings: 2H51 is currently unprofitable.
Growing Profit Margin: 2H51 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2H51 is unprofitable, and losses have increased over the past 5 years at a rate of 17.2% per year.
Accelerating Growth: Unable to compare 2H51's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2H51 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 2H51 has a negative Return on Equity (-125.88%), as it is currently unprofitable.